News FDA to review Sanofi's Dupixent in asthma The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema.
News Rumours of $1.65bn GSK bid for respiratory partners Vectura GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.
News AZ's asthma drug Fasenra approved in EU A further 3,400 children are eligible for treatment with Orkambi
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
